Floatz logo

Nivolumab

Extramammary Paget Disease

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Extramammary Paget Disease cohort.

Asset / SponsorPhaseRating
Ivocizumab
Fudan University
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1CC
mq719
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →